Gavin D Perkins1, Ranjit Lall2, Tom Quinn3, Charles D Deakin4, Matthew W Cooke2, Jessica Horton2, Sarah E Lamb5, Anne-Marie Slowther2, Malcolm Woollard3, Andy Carson6, Mike Smyth7, Richard Whitfield8, Amanda Williams8, Helen Pocock9, John J M Black9, John Wright10, Kyee Han11, Simon Gates2. 1. Warwick Clinical Trials Unit, University of Warwick, Coventry, UK; Heart of England NHS Foundation Trust, Birmingham, UK. Electronic address: g.d.perkins@warwick.ac.uk. 2. Warwick Clinical Trials Unit, University of Warwick, Coventry, UK. 3. Surrey Peri-operative Anaesthesia Critical care collaborative Research Group, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK. 4. Surrey Peri-operative Anaesthesia Critical care collaborative Research Group, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK; South Central Ambulance Service NHS Foundation Trust, Otterbourne, UK; NIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton Hampshire. 5. Warwick Clinical Trials Unit, University of Warwick, Coventry, UK; University of Oxford, Oxford, UK. 6. West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, UK. 7. Warwick Clinical Trials Unit, University of Warwick, Coventry, UK; West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, UK. 8. Welsh Ambulance Services NHS Trust, Denbighshire, Wales, UK. 9. South Central Ambulance Service NHS Foundation Trust, Otterbourne, UK. 10. North East Ambulance Service NHS Foundation Trust, Newcastle upon Tyne, UK; Royal Victoria Infirmary, Newcastle upon Tyne, UK. 11. North East Ambulance Service NHS Foundation Trust, Newcastle upon Tyne, UK.
Abstract
BACKGROUND:Mechanical chest compression devices have the potential to help maintain high-quality cardiopulmonary resuscitation (CPR), but despite their increasing use, little evidence exists for their effectiveness. We aimed to study whether the introduction of LUCAS-2 mechanical CPR into front-line emergency response vehicles would improve survival from out-of-hospital cardiac arrest. METHODS: The pre-hospital randomised assessment of a mechanical compression device in cardiac arrest (PARAMEDIC) trial was a pragmatic, cluster-randomised open-label trial including adults with non-traumatic, out-of-hospital cardiac arrest from four UK Ambulance Services (West Midlands, North East England, Wales, South Central). 91 urban and semi-urban ambulance stations were selected for participation. Clusters were ambulance service vehicles, which were randomly assigned (1:2) to LUCAS-2 or manual CPR. Patients received LUCAS-2 mechanical chest compression or manual chest compressions according to the first trial vehicle to arrive on scene. The primary outcome was survival at 30 days following cardiac arrest and was analysed by intention to treat. Ambulance dispatch staff and those collecting the primary outcome were masked to treatment allocation. Masking of the ambulance staff who delivered the interventions and reported initial response to treatment was not possible. The study is registered with Current Controlled Trials, number ISRCTN08233942. FINDINGS: We enrolled 4471 eligible patients (1652 assigned to the LUCAS-2 group, 2819 assigned to the control group) between April 15, 2010 and June 10, 2013. 985 (60%) patients in the LUCAS-2 group received mechanical chest compression, and 11 (<1%) patients in the control group received LUCAS-2. In the intention-to-treat analysis, 30 day survival was similar in the LUCAS-2 group (104 [6%] of 1652 patients) and in the manual CPR group (193 [7%] of 2819 patients; adjusted odds ratio [OR] 0·86, 95% CI 0·64-1·15). No serious adverse events were noted. Seven clinical adverse events were reported in the LUCAS-2 group (three patients with chest bruising, two with chest lacerations, and two with blood in mouth). 15 device incidents occurred during operational use. No adverse or serious adverse events were reported in the manual group. INTERPRETATION: We noted no evidence of improvement in 30 day survival with LUCAS-2 compared with manual compressions. On the basis of ours and other recent randomised trials, widespread adoption of mechanical CPR devices for routine use does not improve survival. FUNDING: National Institute for Health Research HTA - 07/37/69.
RCT Entities:
BACKGROUND: Mechanical chest compression devices have the potential to help maintain high-quality cardiopulmonary resuscitation (CPR), but despite their increasing use, little evidence exists for their effectiveness. We aimed to study whether the introduction of LUCAS-2 mechanical CPR into front-line emergency response vehicles would improve survival from out-of-hospital cardiac arrest. METHODS: The pre-hospital randomised assessment of a mechanical compression device in cardiac arrest (PARAMEDIC) trial was a pragmatic, cluster-randomised open-label trial including adults with non-traumatic, out-of-hospital cardiac arrest from four UK Ambulance Services (West Midlands, North East England, Wales, South Central). 91 urban and semi-urban ambulance stations were selected for participation. Clusters were ambulance service vehicles, which were randomly assigned (1:2) to LUCAS-2 or manual CPR. Patients received LUCAS-2 mechanical chest compression or manual chest compressions according to the first trial vehicle to arrive on scene. The primary outcome was survival at 30 days following cardiac arrest and was analysed by intention to treat. Ambulance dispatch staff and those collecting the primary outcome were masked to treatment allocation. Masking of the ambulance staff who delivered the interventions and reported initial response to treatment was not possible. The study is registered with Current Controlled Trials, number ISRCTN08233942. FINDINGS: We enrolled 4471 eligible patients (1652 assigned to the LUCAS-2 group, 2819 assigned to the control group) between April 15, 2010 and June 10, 2013. 985 (60%) patients in the LUCAS-2 group received mechanical chest compression, and 11 (<1%) patients in the control group received LUCAS-2. In the intention-to-treat analysis, 30 day survival was similar in the LUCAS-2 group (104 [6%] of 1652 patients) and in the manual CPR group (193 [7%] of 2819 patients; adjusted odds ratio [OR] 0·86, 95% CI 0·64-1·15). No serious adverse events were noted. Seven clinical adverse events were reported in the LUCAS-2 group (three patients with chest bruising, two with chest lacerations, and two with blood in mouth). 15 device incidents occurred during operational use. No adverse or serious adverse events were reported in the manual group. INTERPRETATION: We noted no evidence of improvement in 30 day survival with LUCAS-2 compared with manual compressions. On the basis of ours and other recent randomised trials, widespread adoption of mechanical CPR devices for routine use does not improve survival. FUNDING: National Institute for Health Research HTA - 07/37/69.
Authors: F von Matthey; K F Braun; M Hanschen; F Pohlig; E C Schubert; E Matevossian; P Hoppmann; K-G Kanz; P Biberthaler Journal: Unfallchirurg Date: 2016-01 Impact factor: 1.000
Authors: M Bernhard; N H Behrens; J Wnent; S Seewald; S Brenner; T Jantzen; A Bohn; J T Gräsner; M Fischer Journal: Anaesthesist Date: 2018-01-04 Impact factor: 1.041
Authors: Christian Jung; Kyra Janssen; Mirko Kaluza; Georg Fuernau; Tudor Constantin Poerner; Michael Fritzenwanger; Ruediger Pfeifer; Holger Thiele; Hans Reiner Figulla Journal: Clin Res Cardiol Date: 2015-08-25 Impact factor: 5.460